TY - JOUR
T1 - Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease
AU - Dominantly Inherited Alzheimer Network (DIAN)
AU - Valdes, Phoebe
AU - Caldwell, Andrew B.
AU - Liu, Qing
AU - Fitzgerald, Michael Q.
AU - Ramachandran, Srinivasan
AU - Karch, Celeste M.
AU - Xu, Xiong
AU - Xu, Jinbin
AU - Xiong, Chengjie
AU - Weamer, Elise
AU - Wang, Qing
AU - Wang, Peter
AU - Vöglein, Jonathan
AU - Thompson, Sarah
AU - Taddei, Kevin
AU - Stephens, Sochenda
AU - Sohrabi, Hamid
AU - Snitz, Beth
AU - Smith, Lori
AU - Smith, Jennifer
AU - Sigurdson, Wendy
AU - Shimada, Hiroyuki
AU - Shady, Kristine
AU - Seyfried, Nicholas T.
AU - Senda, Michio
AU - Schofield, Peter
AU - Salloway, Stephen
AU - Ringman, John
AU - Renton, Alan
AU - Preische, Oliver
AU - Ping, Lingyan
AU - Perrin, Richard
AU - Patira, Riddhi
AU - O’Connor, Antoinette
AU - Obermüller, Ulricke
AU - Nuscher, Brigitte
AU - Norton, Joanne
AU - Noble, James
AU - Niimi, Yoshiki
AU - Neimeyer, Katie
AU - Nagamatsu, Akemi
AU - Nadkarni, Neelesh
AU - Mummery, Cath
AU - Mountz, James
AU - Morris, John
AU - Morenas-Rodriguez, Estrella
AU - Mejia, Arlene
AU - McDade, Eric
AU - McCullough, Austin
AU - Goate, Alison
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Background: PSEN1, PSEN2, and APP mutations cause Alzheimer’s disease (AD) with an early age at onset (AAO) and progressive cognitive decline. PSEN1 mutations are more common and generally have an earlier AAO; however, certain PSEN1 mutations cause a later AAO, similar to those observed in PSEN2 and APP. Methods: We examined whether common disease endotypes exist across these mutations with a later AAO (~ 55 years) using hiPSC-derived neurons from familial Alzheimer’s disease (FAD) patients harboring mutations in PSEN1A79V, PSEN2N141I, and APPV717I and mechanistically characterized by integrating RNA-seq and ATAC-seq. Results: We identified common disease endotypes, such as dedifferentiation, dysregulation of synaptic signaling, repression of mitochondrial function and metabolism, and inflammation. We ascertained the master transcriptional regulators associated with these endotypes, including REST, ASCL1, and ZIC family members (activation), and NRF1 (repression). Conclusions: FAD mutations share common regulatory changes within endotypes with varying severity, resulting in reversion to a less-differentiated state. The regulatory mechanisms described offer potential targets for therapeutic interventions.
AB - Background: PSEN1, PSEN2, and APP mutations cause Alzheimer’s disease (AD) with an early age at onset (AAO) and progressive cognitive decline. PSEN1 mutations are more common and generally have an earlier AAO; however, certain PSEN1 mutations cause a later AAO, similar to those observed in PSEN2 and APP. Methods: We examined whether common disease endotypes exist across these mutations with a later AAO (~ 55 years) using hiPSC-derived neurons from familial Alzheimer’s disease (FAD) patients harboring mutations in PSEN1A79V, PSEN2N141I, and APPV717I and mechanistically characterized by integrating RNA-seq and ATAC-seq. Results: We identified common disease endotypes, such as dedifferentiation, dysregulation of synaptic signaling, repression of mitochondrial function and metabolism, and inflammation. We ascertained the master transcriptional regulators associated with these endotypes, including REST, ASCL1, and ZIC family members (activation), and NRF1 (repression). Conclusions: FAD mutations share common regulatory changes within endotypes with varying severity, resulting in reversion to a less-differentiated state. The regulatory mechanisms described offer potential targets for therapeutic interventions.
UR - http://www.scopus.com/inward/record.url?scp=85214110995&partnerID=8YFLogxK
U2 - 10.1186/s13195-024-01659-6
DO - 10.1186/s13195-024-01659-6
M3 - Article
AN - SCOPUS:85214110995
SN - 1758-9193
VL - 17
JO - Alzheimer's Research and Therapy
JF - Alzheimer's Research and Therapy
IS - 1
M1 - 5
ER -